TNNC2

Summary

TNNC2 (troponin C2, fast skeletal type, HGNC:11944) is a protein-coding gene on chromosome 20q13.12, encoding Troponin C, skeletal muscle (P02585). Troponin is the central regulatory protein of striated muscle contraction.

Troponin (Tn), a key protein complex in the regulation of striated muscle contraction, is composed of 3 subunits. The Tn-I subunit inhibits actomyosin ATPase, the Tn-T subunit binds tropomyosin and Tn-C, while the Tn-C subunit binds calcium and overcomes the inhibitory action of the troponin complex on actin filaments. The protein encoded by this gene is the Tn-C subunit.

Source: NCBI Gene 7125 — RefSeq curated summary.

At a glance

• Gene–disease (curated): congenital myopathy 15 (Strong, GenCC) — +1 more curated relationship
• Clinical variants (ClinVar): 14 total — 2 pathogenic
• Phenotypes (HPO): 18
• Druggable target: yes
• MANE Select transcript: NM_003279

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11944
Approved symbol	TNNC2
Name	troponin C2, fast skeletal type
Location	20q13.12
Locus type	gene with protein product
Status	Approved
Aliases	FAP85, CFAP85
Ensembl gene	ENSG00000101470
Ensembl biotype	protein_coding
OMIM	191039
Entrez	7125

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000372555, ENST00000372557

RefSeq mRNA: 1 — MANE Select: NM_003279 NM_003279

CCDS: CCDS13375

Canonical transcript exons

ENST00000372555 — 6 exons

Exon	Start	End
ENSE00000662419	45824292	45824406
ENSE00000662420	45824495	45824638
ENSE00000845047	45823991	45824127
ENSE00001458086	45827246	45827312
ENSE00001458091	45823214	45823379
ENSE00003573925	45824783	45824834

Expression profiles

Bgee: expression breadth ubiquitous, 190 present calls, max score 99.97.

FANTOM5 (CAGE): breadth broad, TPM avg 38.2120 / max 10692.8820, expressed in 217 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
187491	37.1352	158
187490	0.2312	28
187485	0.2037	24
187486	0.1725	24
187488	0.1235	23
187484	0.0992	18
187487	0.0901	19
209144	0.0881	40
187489	0.0684	15

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	99.97	gold quality
gastrocnemius	UBERON:0001388	99.94	gold quality
hindlimb stylopod muscle	UBERON:0004252	99.94	gold quality
diaphragm	UBERON:0001103	99.93	gold quality
quadriceps femoris	UBERON:0001377	99.92	gold quality
vastus lateralis	UBERON:0001379	99.92	gold quality
skeletal muscle tissue	UBERON:0001134	99.90	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	99.90	gold quality
biceps brachii	UBERON:0001507	99.89	gold quality
body of tongue	UBERON:0011876	99.88	gold quality
triceps brachii	UBERON:0001509	99.87	gold quality
deltoid	UBERON:0001476	99.85	gold quality
gluteal muscle	UBERON:0002000	99.81	gold quality
tibialis anterior	UBERON:0001385	99.64	gold quality
muscle organ	UBERON:0001630	99.23	gold quality
muscle of leg	UBERON:0001383	98.97	gold quality
muscle tissue	UBERON:0002385	92.81	gold quality
tongue	UBERON:0001723	91.62	gold quality
pharyngeal mucosa	UBERON:0000355	89.80	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.43	gold quality
mucosa of transverse colon	UBERON:0004991	86.86	gold quality
monocyte	CL:0000576	85.70	gold quality
mononuclear cell	CL:0000842	85.37	gold quality
superior surface of tongue	UBERON:0007371	84.36	gold quality
leukocyte	CL:0000738	84.31	gold quality
tendon of biceps brachii	UBERON:0008188	83.58	silver quality
trabecular bone tissue	UBERON:0002483	80.94	gold quality
minor salivary gland	UBERON:0001830	80.49	gold quality
popliteal artery	UBERON:0002250	79.31	gold quality
tibial artery	UBERON:0007610	79.28	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-56	yes	5959.60
E-MTAB-8410	yes	16.61
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

6 targeting TNNC2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-6868-3P	98.63	69.64	2259
HSA-MIR-7114-3P	98.42	66.53	569
HSA-MIR-1180-5P	98.16	65.32	460
HSA-MIR-3667-5P	97.16	64.87	591
HSA-MIR-1281	92.96	65.73	260

Literature-anchored findings (GeneRIF, showing 3)

• Bioinformatics-based discovery of PYGM and TNNC2 as potential biomarkers of head and neck squamous cell carcinoma. (PMID:31324732)
• A Mechanism Underlying Sex-Associated Differences in Ankylosing Spondylitis: Troponin C2, Fast Skeletal Type (TNNC2) and Calcium Signaling Pathway. (PMID:33052895)
• Pathogenic variants in TNNC2 cause congenital myopathy due to an impaired force response to calcium. (PMID:33755597)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	tnnc2.2	ENSDARG00000070835
danio_rerio	tnnc2.1	ENSDARG00000095002
mus_musculus	Tnnc2	ENSMUSG00000017300
rattus_norvegicus	Tnnc2	ENSRNOG00000015155

Paralogs (1): TNNC1 (ENSG00000114854)

Protein

Protein identifiers

Troponin C, skeletal muscle — P02585 (reviewed: P02585)

All UniProt accessions (2): P02585, C9J7T9

UniProt curated annotations — full annotation on UniProt →

Function. Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C. The binding of calcium to Tn-C abolishes the inhibitory action of Tn on actin filaments.

Disease relevance. Congenital myopathy 15 (CMYO15) [MIM:620161] An autosomal dominant myopathy characterized by neonatal onset of hypotonia, muscle weakness, and respiratory muscle involvement resulting in severe respiratory insufficiency. The disorder improves over time, although forced vital capacity remains decreased. Other features include facial weakness, often with ptosis or external ophthalmoplegia, jaw or distal joint contractures, scoliosis, and osteopenia. The disease is caused by variants affecting the gene represented in this entry.

Miscellaneous. Skeletal muscle troponin C binds four calcium ions.

Similarity. Belongs to the troponin C family.

RefSeq proteins (1): NP_003270* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002048	EF_hand_dom	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR018247	EF_Hand_1_Ca_BS	Binding_site
IPR050230	CALM/Myosin/TropC-like	Family

Pfam: PF13499

UniProt features (37 total): binding site 19, helix 6, domain 4, sequence variant 2, sequence conflict 2, initiator methionine 1, chain 1, modified residue 1, strand 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
7KAA	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P02585-F1	84.09	0.26

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (19): 64; 66; 68; 70; 75; 104; 106; 108; 110; 115; 140; 142 …

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-390522	Striated Muscle Contraction

MSigDB gene sets: 187 (showing top): GCANCTGNY_MYOD_Q6, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, HUMMERICH_BENIGN_SKIN_TUMOR_DN, HUMMERICH_MALIGNANT_SKIN_TUMOR_DN, GOBP_MULTICELLULAR_ORGANISMAL_MOVEMENT, MEF2_02, LEE_LIVER_CANCER_CIPROFIBRATE_DN, GOBP_SKELETAL_MUSCLE_CONTRACTION, CAGCTG_AP4_Q5, HUMMERICH_SKIN_CANCER_PROGRESSION_DN, CEBPB_01, GOBP_REGULATION_OF_MUSCLE_CONTRACTION, GOBP_MUSCLE_CONTRACTION, GOBP_REGULATION_OF_SYSTEM_PROCESS, LEE_LIVER_CANCER_DENA_DN

GO Biological Process (2): skeletal muscle contraction (GO:0003009), regulation of muscle contraction (GO:0006937)

GO Molecular Function (4): calcium ion binding (GO:0005509), actin binding (GO:0003779), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (2): cytosol (GO:0005829), troponin complex (GO:0005861)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Muscle contraction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
striated muscle contraction	1
musculoskeletal movement	1
muscle contraction	1
regulation of muscle system process	1
metal ion binding	1
cytoskeletal protein binding	1
binding	1
cation binding	1
cytoplasm	1
cellular anatomical structure	1
striated muscle thin filament	1
protein-containing complex	1

Protein interactions and networks

STRING

2210 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TNNC2	TNNT3	P45378	828
TNNC2	TNNI2	P48788	807
TNNC2	TNNI1	P19237	697
TNNC2	MYL11	Q96A32	671
TNNC2	TPM2	P06468	644
TNNC2	TNNT1	P13805	641
TNNC2	ACTN3	Q08043	601
TNNC2	TPM1	P09493	590
TNNC2	MYH4	Q9Y623	585
TNNC2	MYH3	P11055	584
TNNC2	ACTA1	P02568	583
TNNC2	TNNI3	P19429	567
TNNC2	MYH2	Q9UKX2	556
TNNC2	MYH1	P12882	555
TNNC2	ACTN2	P35609	554

IntAct

40 interactions, top by confidence:

A	B	Type	Score
HUS1	RAD1	psi-mi:“MI:0914”(association)	0.840
TNNC2	TBC1D1	psi-mi:“MI:0915”(physical association)	0.670
TNNC2	TNNI3	psi-mi:“MI:0915”(physical association)	0.560
TNNI3	TNNC2	psi-mi:“MI:0915”(physical association)	0.560
NOSIP	TNNC2	psi-mi:“MI:0914”(association)	0.530
KCNAB2	TNNC2	psi-mi:“MI:0915”(physical association)	0.400
TNNC2	PGAM2	psi-mi:“MI:0915”(physical association)	0.400
TMEM186	TNNC2	psi-mi:“MI:0915”(physical association)	0.400
C9orf78	TNNC2	psi-mi:“MI:0915”(physical association)	0.400
TNNC2	PIK3R3	psi-mi:“MI:0915”(physical association)	0.370
DUX4L9	TNNC2	psi-mi:“MI:0915”(physical association)	0.370
TMEM131	CNOT1	psi-mi:“MI:0914”(association)	0.350
MECOM	ATP2A1	psi-mi:“MI:0914”(association)	0.350
RSPH6A	ATP2A1	psi-mi:“MI:0914”(association)	0.350
SNRPC	GNPAT	psi-mi:“MI:0914”(association)	0.350
UBE2W	MARCHF6	psi-mi:“MI:0914”(association)	0.350
PPIL3	SNX3	psi-mi:“MI:0914”(association)	0.350
TNNC2	ECI2	psi-mi:“MI:0914”(association)	0.350
C20orf141	ENDOD1	psi-mi:“MI:0914”(association)	0.350
PRR15	TNNC2	psi-mi:“MI:0914”(association)	0.350
SDHD	TNNC2	psi-mi:“MI:0914”(association)	0.350
C7orf33	TNNC2	psi-mi:“MI:0914”(association)	0.350
TSPAN33	ATP2A1	psi-mi:“MI:0914”(association)	0.350
CD300C	SMPD2	psi-mi:“MI:0914”(association)	0.350

BioGRID (65): TNNI3 (Two-hybrid), TNNC2 (Affinity Capture-MS), TNNC2 (Two-hybrid), TNNC2 (Two-hybrid), TNNC2 (Affinity Capture-MS), TNNC2 (Affinity Capture-MS), TNNC2 (Two-hybrid), TNNC2 (Affinity Capture-MS), TNNC2 (Affinity Capture-MS), TNNC2 (Affinity Capture-MS), TNNC2 (Affinity Capture-MS), TNNC2 (Affinity Capture-MS), TNNC2 (Affinity Capture-MS), POGZ (Affinity Capture-MS), ZBTB21 (Affinity Capture-MS)

ESM2 similar proteins: A0T2M3, O64943, P02585, P04110, P06706, P06707, P06708, P20801, P21797, P29289, P29290, P29291, P35622, Q0IQB6, Q0IUU4, Q2R1Z5, Q3SB08, Q3SB09, Q3SB10, Q3SB11, Q3SB12, Q3SB13, Q3SB14, Q3SB15, Q6BWS8, Q84MN0, Q8AY75, Q8S1Y9, Q8TD86, Q94AZ4, Q9BLG0, Q9C8Y1, Q9C9U8, Q9FYK2, Q9JM83, Q9LE22, Q9LF55, Q9LNE7, Q9LPK5, Q9LQN4

Diamond homologs: A0A125YZN2, A0T2M3, A2WN93, A2Y609, A3E3H0, A3E4D8, A3E4F9, A4UHC0, A8CEP3, A8I1Q0, O00897, O23184, O60041, O64943, O82018, O94739, P02585, P02597, P02598, P04352, P04353, P04464, P05419, P06707, P06787, P07463, P0DH95, P0DH96, P11120, P11121, P15094, P18061, P21797, P21798, P25070, P25071, P27165, P27166, P29289, P29290

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
“MYOD1/SWI/SNF complex”	“up-regulates quantity by expression”	TNNC2	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

14 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	10
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1806474	NM_003279.3(TNNC2):c.100G>T (p.Asp34Tyr)	Pathogenic
1806475	NM_003279.3(TNNC2):c.237G>C (p.Met79Ile)	Pathogenic

SpliceAI

478 predictions. Top by Δscore:

Variant	Effect	Δscore
20:45823378:CT:C	acceptor_gain	1.0000
20:45823380:C:CC	acceptor_gain	1.0000
20:45823986:CTCA:C	donor_loss	1.0000
20:45823987:TCACC:T	donor_loss	1.0000
20:45823988:CACC:C	donor_loss	1.0000
20:45823989:A:AC	donor_gain	1.0000
20:45823990:C:CC	donor_gain	1.0000
20:45823990:CCG:C	donor_gain	1.0000
20:45823990:CCGT:C	donor_gain	1.0000
20:45824137:C:CT	acceptor_gain	1.0000
20:45824138:G:T	acceptor_gain	1.0000
20:45824288:GCAC:G	donor_loss	1.0000
20:45824289:CA:C	donor_loss	1.0000
20:45824290:A:AT	donor_loss	1.0000
20:45824291:C:CA	donor_loss	1.0000
20:45824403:CTGC:C	acceptor_gain	1.0000
20:45824404:TGC:T	acceptor_gain	1.0000
20:45824404:TGCC:T	acceptor_loss	1.0000
20:45824406:CCTG:C	acceptor_loss	1.0000
20:45824407:C:CC	acceptor_gain	1.0000
20:45824491:TCACC:T	donor_loss	1.0000
20:45824493:A:AC	donor_gain	1.0000
20:45824493:ACCGT:A	donor_gain	1.0000
20:45824494:C:CC	donor_gain	1.0000
20:45824494:CCGT:C	donor_gain	1.0000
20:45824494:CCGTC:C	donor_gain	1.0000
20:45824497:T:A	donor_gain	1.0000
20:45824509:T:TA	donor_gain	1.0000
20:45824634:GAACT:G	acceptor_gain	1.0000
20:45824635:AACT:A	acceptor_gain	1.0000

AlphaMissense

1107 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:45824378:G:C	F76L	1.000
20:45824378:G:T	F76L	1.000
20:45824380:A:G	F76L	1.000
20:45824622:A:C	F24L	1.000
20:45824622:A:T	F24L	1.000
20:45824624:A:G	F24L	1.000
20:45824307:A:G	F100S	0.999
20:45824504:C:G	D64H	0.999
20:45824527:A:G	L56P	0.999
20:45824575:A:G	L40S	0.999
20:45824038:A:G	L135P	0.998
20:45824095:A:G	L116P	0.998
20:45824110:A:T	I111N	0.998
20:45824306:G:C	F100L	0.998
20:45824306:G:T	F100L	0.998
20:45824308:A:G	F100L	0.998
20:45824379:A:G	F76S	0.998
20:45824394:A:T	I71N	0.998
20:45824503:T:A	D64V	0.998
20:45824503:T:G	D64A	0.998
20:45824590:A:T	I35N	0.998
20:45824613:A:C	F27L	0.998
20:45824613:A:T	F27L	0.998
20:45824615:A:G	F27L	0.998
20:45824623:A:G	F24S	0.998
20:45823376:A:G	F152S	0.997
20:45824011:T:A	D144V	0.997
20:45824023:T:G	D140A	0.997
20:45824116:C:A	G109V	0.997
20:45824295:T:G	D104A	0.997

dbSNP variants (sampled 300 via entrez): RS1000528307 (20:45823546 G>A), RS1000573167 (20:45829807 A>G), RS1000587637 (20:45825912 G>A,C), RS1000654231 (20:45827623 T>C), RS1000972499 (20:45833754 C>A,T), RS1001109810 (20:45833347 T>C), RS1001599717 (20:45824314 C>G,T), RS1001693283 (20:45832189 A>G), RS1001904030 (20:45823105 C>T), RS1002032038 (20:45830428 T>A), RS1002196964 (20:45833958 G>A,T), RS1002336692 (20:45822982 A>G), RS1002586061 (20:45823144 C>A,T), RS1002729036 (20:45833520 C>T), RS1002943923 (20:45823330 G>A)

Disease associations

OMIM: gene MIM:191039 | disease phenotypes: MIM:620161

GenCC curated gene-disease

Disease	Classification	Inheritance
congenital myopathy 15	Strong	Autosomal dominant
hypertrophic cardiomyopathy	No Known Disease Relationship	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
hypertrophic cardiomyopathy	No Known Disease Relationship	AD

Mondo (2): congenital myopathy 15 (MONDO:0859335), hypertrophic cardiomyopathy (MONDO:0005045)

Orphanet (0):

HPO phenotypes

18 total (18 of 18 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000938	Osteopenia
HP:0001252	Hypotonia
HP:0001270	Motor delay
HP:0001324	Muscle weakness
HP:0001382	Joint hypermobility
HP:0001558	Decreased fetal movement
HP:0001561	Polyhydramnios
HP:0001605	Vocal cord paralysis
HP:0002515	Waddling gait
HP:0003557	Increased variability in muscle fiber diameter
HP:0003577	Congenital onset
HP:0003803	Type 1 muscle fiber predominance
HP:0005180	Tricuspid regurgitation
HP:0012385	Camptodactyly
HP:0012548	Fatty replacement of skeletal muscle
HP:0030319	Weakness of facial musculature
HP:0032341	Reduced forced vital capacity

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D002312	Cardiomyopathy, Hypertrophic	C14.280.238.100; C14.280.484.048.750.070.160

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3831282 (PROTEIN COMPLEX)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
entinostat	increases expression, affects cotreatment	2
Valproic Acid	affects expression, increases expression	2
aristolochic acid I	increases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
bisphenol A	affects cotreatment, increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
benzo(e)pyrene	increases methylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
licochalcone B	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
incobotulinumtoxinA	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation	1
Carbamazepine	affects expression	1
Cisplatin	affects cotreatment, decreases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Estradiol	affects expression	1
Indomethacin	increases expression, affects cotreatment	1
Methapyrilene	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Triclosan	decreases expression	1
Urethane	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Cadmium Chloride	decreases expression	1
Copper Sulfate	increases expression	1

Clinical trials (associated diseases)

227 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00879060	PHASE4	COMPLETED	Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
NCT01721967	PHASE4	COMPLETED	Ranolazine for the Treatment of Chest Pain in HCM Patients
NCT02948998	PHASE4	UNKNOWN	Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy
NCT03249272	PHASE4	TERMINATED	Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
NCT04133532	PHASE4	COMPLETED	Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy
NCT06401343	PHASE4	RECRUITING	Use of SGLT2i in noHCM With HFpEF
NCT07103655	PHASE4	NOT_YET_RECRUITING	The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
NCT07600177	PHASE4	RECRUITING	Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT00317967	PHASE3	COMPLETED	Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart
NCT00698074	PHASE3	UNKNOWN	Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy
NCT00821353	PHASE3	COMPLETED	Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy
NCT02431221	PHASE3	WITHDRAWN	Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure
NCT03470545	PHASE3	COMPLETED	Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT05174416	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
NCT05182658	PHASE3	ACTIVE_NOT_RECRUITING	Empagliflozin in Hypertrophic Cardiomyopathy
NCT05186818	PHASE3	COMPLETED	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
NCT05767346	PHASE3	COMPLETED	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
NCT06116968	PHASE3	COMPLETED	An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
NCT06873828	PHASE3	NOT_YET_RECRUITING	Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
NCT07021976	PHASE3	RECRUITING	A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT07023341	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT07202897	PHASE3	NOT_YET_RECRUITING	LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
NCT00001631	PHASE2	COMPLETED	Study of Blood Flow in Heart Muscle
NCT00001894	PHASE2	COMPLETED	A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy
NCT00001960	PHASE2	COMPLETED	Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle
NCT00011076	PHASE2	COMPLETED	Pirfenidone to Treat Hypertrophic Cardiomyopathy
NCT00035386	PHASE2	COMPLETED	Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study
NCT00430833	PHASE2	UNKNOWN	CHANCE - Candesartan in Hypertrophic Cardiomyopathy
NCT00500552	PHASE2	COMPLETED	Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy
NCT01150461	PHASE2	COMPLETED	Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy
NCT01230918	PHASE2	TERMINATED	Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis
NCT01447654	PHASE2	COMPLETED	Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy
NCT01696370	PHASE2	UNKNOWN	Trimetazidine Therapy in Hypertrophic Cardiomyopathy
NCT01912534	PHASE2	COMPLETED	Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
NCT02590809	PHASE2	COMPLETED	Hypertrophic Cardiomyopathy Symptom Release by BX1514M
NCT03496168	PHASE2	COMPLETED	Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER
NCT03532802	PHASE2	COMPLETED	The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.
NCT03832660	PHASE2	COMPLETED	Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy
NCT04219826	PHASE2	COMPLETED	Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy
NCT04426578	PHASE2	UNKNOWN	Role of Perhexiline in Hypertrophic Cardiomyopathy